CareLit · DOI-Nachweis · Zeitschrift für Gastroenterologie
The HER2 heterodimerization inhibitor pertuzumab is active against colon cancer cells in vitro and in vivo
DOI 10.1055/s-2005-920163
Bibliografische Angaben
Nachweis in CareLit
Autor:innenN Andre, A Schoeneck, I Schwarte-Waldhoff, M Hasmann, W Schmiegel, A Reinacher-Schick
ZeitschriftZeitschrift für Gastroenterologie
Ausgabe04/2006
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Aims: 60–80% of all colon cancers show an upregulation of HER1/EGFR while their HER2-expression is variable and ranges from 20% in early stages up to 80% in metastatic disease. Both HER1/EGFR and HER2 overexpression may be associated with poor prognosis. Pertuzumab is a new antibody targeting HER2 and the first member of the new class of HER-dimerization inhibitors (HDI) which inhibit ligand dependent and independen…
Zitieren
Zitierempfehlung
N Andre, A Schoeneck, I Schwarte-Waldhoff, M Hasmann, W Schmiegel, A Reinacher-Schick (2006) The HER2 heterodimerization inhibitor pertuzumab is active against colon cancer cells in vitro and in vivo. Zeitschrift für Gastroenterologie (04). https://doi.org/10.1055/s-2005-920163
Mit CareLit weiterarbeiten